The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression.
 
Tyler F. Stewart
Consulting or Advisory Role - AstraZeneca; Seattle Genetics/Astellas
Research Funding - GRAIL
 
Sarah Elizabeth Fenton
No Relationships to Disclose
 
Shayan Nazari
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Andrew Elliott
Employment - Caris Life Sciences
 
Rohan Garje
Research Funding - Amgen (Inst); Endocyte/Advanced Accelerator Applications (Inst); Immunomedics (Inst); Pfizer (Inst); xencor (Inst)
 
Amirali Salmasi
No Relationships to Disclose
 
Aditya Bagrodia
Consulting or Advisory Role - Veracyte
 
Chadi Nabhan
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
David James VanderWeele
Honoraria - Astellas Pharma; Myovant Sciences
Consulting or Advisory Role - Bayer; Janssen
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Curium Pharma (Inst); Fortis (Inst); Harpoon therapeutics (Inst); Janssen Oncology (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Rana R. McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)